Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
Key Highlights
- ➤Q3 net income $54.9 million, driven primarily by a $69.6 million convertible-loan fair-value gain
- ➤AP-SA02 Phase 3 preparations advanced; FDA protocol-design discussions and clinical-material production continue
- ➤Armata received $3.7 million additional DoW funding, bringing cumulative award funding to approximately $32.4 million
- ➤FDA granted AP-SA02 Breakthrough Therapy designation for complicated MSSA or MRSA bacteremia
- ➤Cash and equivalents reached $18.3 million at September 30, 2026, versus $8.7 million year-end 2025
Expert Statements
Deborah Birx, Chief Executive Officer of Armata Pharmaceuticals
“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02,”
Deborah Birx, Chief Executive Officer of Armata Pharmaceuticals
“We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study. Our manufacturing capabilities are well established, critical clinical trial preparations are progressing, and we continue to work closely with the U.S. Food and Drug Administration ("FDA") to finalize the study design. Together, these accomplishments reflect the considerable effort and investment we have made to prepare for this important next stage of development, while maintaining fiscal discipline.”
Deborah Birx, Chief Executive Officer of Armata Pharmaceuticals
“We believe the FDA's recent Breakthrough Therapy designation further underscores AP-SA02's clinical potential. We also appreciate the continued financial support of the U.S. Department of War ("DoW"), which comes at an important time as we prepare for this next critical stage of clinical development. We believe AP-SA02 has the potential to make a meaningful difference in patient care and, more broadly, provide a foundation for expanding our bacteriophage technology into additional indications. We are excited about the opportunity ahead and remain firmly focused on successfully executing our Phase 3 program,”
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update PR Newswire
LOS ANGELES, Nov. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2026, and provided a corporate update.
Get started
Create a free account to read the full story.